Lakewood-Amedex Biotherapeutics Inc. Research and Development Expense
Lakewood-Amedex Biotherapeutics Inc. (LABT) reported Research and Development Expense of $503.02 thousand for the 3-month period ending 2026-06-30, per its S-1 filed 2026-09-18.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-09-18
- Lakewood-Amedex Biotherapeutics Inc. research and development expense for the quarter ending 2026-06-30 was $503.02K, a 242.42% increase year-over-year.
- Lakewood-Amedex Biotherapeutics Inc. research and development expense for the quarter ending 2026-03-31 was $182.15K, a 7.33% increase year-over-year.
- Lakewood-Amedex Biotherapeutics Inc. research and development expense for the quarter ending 2025-06-30 was $146.90K.
- Lakewood-Amedex Biotherapeutics Inc. research and development expense for the quarter ending 2025-03-31 was $169.70K.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 12 month |
|---|---|---|---|
| 2026-06-30 | $503.02K S-1 · filed 2026-09-18 | $685.17K S-1 · filed 2026-09-18 | |
| 2026-03-31 | $182.15K 10-Q · filed 2026-05-22 | ||
| 2025-12-31 | $1.26M S-1 · filed 2026-09-18 | ||
| 2025-06-30 | $146.90K S-1 · filed 2026-09-18 | $316.61K S-1 · filed 2026-09-18 | |
| 2025-03-31 | $169.70K 10-Q · filed 2026-05-22 | ||
| 2024-12-31 | $2.10M S-1 · filed 2026-09-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B |